Kari Grønås
Director/Miembro de la Junta en SPAGO NANOMEDICAL AB .
Fortuna: 4 185 $ al 30/04/2024
Perfil
Kari Grønås currently works at Spago Nanomedical AB, as Independent Director from 2018, Ultimovacs ASA, as Director from 2019, K & K AS, as Managing Director & Director from 2012, Norwegian Cancer Society, as Director, and Arxx Therapeutics AS, as Director.
Ms. Grønås also formerly worked at Norwegian Pharmaceutical Society, as Chairman, Oncopeptides AB, as Director, Lytix Biopharma AS, as Director, BerGenBio ASA, as Independent Non-Executive Director from 2016 to 2019, SoftOx Solutions AS, as Non-Executive Director, and Algeta ASA, as Senior Vice President-Operations.
Ms. Grønås received her graduate degree from the University of Oslo.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ULTIMOVACS AS
0.02% | 31/12/2022 | 6 640 ( 0.02% ) | 4 185 $ | 30/04/2024 |
Cargos activos de Kari Grønås
| Empresas | Cargo | Inicio |
|---|---|---|
| SPAGO NANOMEDICAL AB | Director/Miembro de la Junta | 01/01/2018 |
| ULTIMOVACS ASA | Director/Miembro de la Junta | 01/01/2019 |
K & K AS
 K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Director Ejecutivo | 21/05/2012 |
| Norwegian Cancer Society | Director/Miembro de la Junta | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Kari Grønås.
| Empresas | Cargo | Fin |
|---|---|---|
| BERGENBIO ASA | Director/Miembro de la Junta | 13/03/2019 |
| ONCOPEPTIDES AB | Director/Miembro de la Junta | - |
| SOFTOX SOLUTIONS | Director/Miembro de la Junta | - |
| Norwegian Pharmaceutical Society | Presidente | - |
| ░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - |
Formación de Kari Grønås.
| University of Oslo | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 6 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| BERGENBIO ASA | Health Technology |
| SPAGO NANOMEDICAL AB | Health Technology |
| ULTIMOVACS ASA | Health Technology |
| SOFTOX SOLUTIONS | Commercial Services |
| Empresas privadas | 5 |
|---|---|
| Norwegian Pharmaceutical Society | |
K & K AS
K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Commercial Services |
| Norwegian Cancer Society | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Bolsa de valores
- Insiders
- Kari Grønås
